Biogen Idec Inc (BIIB) news: Biogen's Winning Strategy Seeking Alpha In the same segment Biogen and partner AbbVie (ABBV) are developing daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis. The companies have completed a Phase 2b trial and expect the results of the Phase 3 study in mid-2014. |
